Showing results (101-110 of 114) with videos related to
Sort By:
Pageof 12
BMC Psychiatry|June 28, 2023
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.Biological Psychiatry|February 16, 2016
Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese PopulationTakeo Saito, Masashi Ikeda, Taisei Mushiroda, et al.The International Journal of Neuropsychopharmacology|June 20, 2022
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide StudyShinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, et al.Neuropsychopharmacology Reports|November 17, 2022
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood DisordersKentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, et al.Asian Journal of Psychiatry|June 6, 2022
Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site studyHiroyuki Muraoka, Fumitoshi Kodaka, Naomi Hasegawa, et al.Journal of Clinical Psychopharmacology|May 22, 2023
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in JapanToshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, et al.Asian Journal of Psychiatry|January 20, 2022
The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE projectKayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, et al.Neuropsychopharmacology Reports|October 18, 2022
Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia"Ken Inada, Kentaro Fukumoto, Naomi Hasegawa, et al.Frontiers in Psychiatry|June 3, 2022
Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital CharacteristicsHikaru Hori, Norio Yasui-Furukori, Naomi Hasegawa, et al.Frontiers in Neuroscience|July 17, 2020
Brainstem Organoids From Human Pluripotent Stem CellsNobuyuki Eura, Takeshi K Matsui, Joachim Luginbühl, et al.Pageof 12